Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

190 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Targeted based therapy in nodal T-cell lymphomas.
Chihara D, Miljkovic M, Iyer SP, Vega F. Chihara D, et al. Among authors: miljkovic m. Leukemia. 2021 Apr;35(4):956-967. doi: 10.1038/s41375-021-01191-8. Epub 2021 Mar 4. Leukemia. 2021. PMID: 33664464 Review.
Cytokines in the Treatment of Cancer.
Conlon KC, Miljkovic MD, Waldmann TA. Conlon KC, et al. J Interferon Cytokine Res. 2019 Jan;39(1):6-21. doi: 10.1089/jir.2018.0019. Epub 2018 Jun 11. J Interferon Cytokine Res. 2019. PMID: 29889594 Free PMC article. Review.
IL-15 in the Combination Immunotherapy of Cancer.
Waldmann TA, Dubois S, Miljkovic MD, Conlon KC. Waldmann TA, et al. Front Immunol. 2020 May 19;11:868. doi: 10.3389/fimmu.2020.00868. eCollection 2020. Front Immunol. 2020. PMID: 32508818 Free PMC article. Review.
Rapid progression of adult T-cell leukemia/lymphoma as tumor-infiltrating Tregs after PD-1 blockade.
Rauch DA, Conlon KC, Janakiram M, Brammer JE, Harding JC, Ye BH, Zang X, Ren X, Olson S, Cheng X, Miljkovic MD, Sundaramoorthi H, Joseph A, Skidmore ZL, Griffith O, Griffith M, Waldmann TA, Ratner L. Rauch DA, et al. Among authors: miljkovic md. Blood. 2019 Oct 24;134(17):1406-1414. doi: 10.1182/blood.2019002038. Blood. 2019. PMID: 31467059 Free PMC article. Clinical Trial.
90Y-Daclizumab (Anti-CD25), High-Dose Carmustine, Etoposide, Cytarabine, and Melphalan Chemotherapy and Autologous Hematopoietic Stem Cell Transplant Yielded Sustained Complete Remissions in 4 Patients with Recurrent Hodgkin's Lymphoma.
Conlon KC, Sportes C, Brechbiel MW, Fowler DH, Gress R, Miljkovic MD, Chen CC, Whatley MA, Bryant BR, Corcoran EM, Kurdziel KA, Pittaluga S, Paik CH, Lee JH, Fleisher TA, Carrasquillo JA, Waldmann TA. Conlon KC, et al. Among authors: miljkovic md. Cancer Biother Radiopharm. 2020 May;35(4):249-261. doi: 10.1089/cbr.2019.3298. Epub 2020 Apr 9. Cancer Biother Radiopharm. 2020. PMID: 32275165 Free PMC article. Clinical Trial.
Short-course IL-15 given as a continuous infusion led to a massive expansion of effective NK cells: implications for combination therapy with antitumor antibodies.
Dubois SP, Miljkovic MD, Fleisher TA, Pittaluga S, Hsu-Albert J, Bryant BR, Petrus MN, Perera LP, Müller JR, Shih JH, Waldmann TA, Conlon KC. Dubois SP, et al. J Immunother Cancer. 2021 Apr;9(4):e002193. doi: 10.1136/jitc-2020-002193. J Immunother Cancer. 2021. PMID: 33883258 Free PMC article. Clinical Trial.
190 results